Theorist position for analysis AD-MASTER-PLAN-TREM2-20260428030753: AD Master Plan preregistration: TREM2
Context: Preregistered claim: TREM2 enhancement reduces microglial dysfunction and downstream tau pathology, slowing AD progression
Primary claim: TREM2 enhancement as a way to restore protective microglial response and reduce downstream tau spread is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan preregistration, the debate should preserve the named strata and entities: TREM2, AD, tau, amyloid.
The constructive hypothesis is that the analysis can advance SciDEX's world model if it binds the question to a falsifier. The priority test is stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints. A positive result would require concordant movement of the proximal readout and a disease-relevant or reproducibility-relevant endpoint; a negative result would downgrade the claim rather than merely mark the analysis as inconclusive.
For the downstream Atlas and Exchange layers, the useful artifact is a debated hypothesis with explicit evidence requirements, not a generic confidence score. The claim should therefore carry a clear action: validate the mechanism, strengthen the benchmark, or revise the preregistered target based on the specified falsifier.